Bone Therapeutics: A unique approach to the development of cell therapy products for bone fracture repair & fracture prevention.




Episode Loading...




PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Bone Therapeutics: A unique approach to the development of cell therapy products for bone fracture repair & fracture prevention.
Released on: January 03, 2017. © PharmaVentures Ltd
Share/save this page:
Email
Bookmark
Facebook
Twitter
LinkedIn
Follow us:
RSS
Twitter
In This Episode:
    Bone Therapeutics is a biotechnology company with a unique approach to the development of cell therapy products for bone fracture repair and fracture prevention.
  • Summary
  • Participants
  • Company
Bone Therapeutics is a biotechnology company with a unique approach to the development of cell therapy products for bone fracture repair and fracture prevention. Bone Therapeutics is creating a new and unique treatment approach using differentiated bone-forming cells administered via a minimally invasive percutaneous procedure, that is expected to offer significant benefits over the current standard-of-care that often involves heavy surgery and long recovery periods.
Mr. Lienard has over 15 years of national and international sales and marketing experience in the pharmaceutical industry. Prior to joining Bone Therapeutics, Mr. Lienard worked at Lundbeck, where he acted as Managing Director for Belgium and Luxemburg and was vital to the launch of several products. He led a team of up to 80 employees, generating over EUR 50 million in sales. Before his position at Lundbeck, Mr. Lienard worked at Eli Lilly and Company, where he held various positions in sales and marketing in Europe and the US, including Sales Director Belgium in 2010. Mr. Lienard started his career in 1999 as consultant at McKinsey & Company. Mr. Lienard graduated from Solvay Brussels School of Economics and Management as Master in Business Engineering in 1999 and obtained a Master of Business Administration (MBA) from Harvard Business School in Boston in 2004. Mr. Lienard joined Bone Therapeutics in 2015 as Chief Business Officer in charge of activities regarding business development and strategic planning and was appointed interim CEO in October 2016.
Bone Therapeutics is a biotechnology company with a unique approach to the development of cell therapy products for bone fracture repair and fracture prevention. Bone Therapeutics is creating a new and unique treatment approach using differentiated bone-forming cells administered via a minimally invasive percutaneous procedure, that is expected to offer significant benefits over the current standard-of-care that often involves heavy surgery and long recovery periods. Today, Bone Therapeutics has 2 first-in-class products, which target 6 indications and offer the potential for additional product extensions: PREOB®, an autologous osteoblastic cell therapy product currently in 2 pivotal Phase IIB/III clinical trials in Europe for the treatment of osteonecrosis and non-union fractures, as well as in a Phase IIA for severe osteoporosis (treatment-resistant osteoporosis); and ALLOB®, an allogeneic (“off-the-shelf”) osteoblastic cell therapy product currently in 3 Phase I/IIA proof-of-concept trials for the treatment of delayed-union fractures, spinal fusion procedures and revision spinal fusion. In addition, Bone Therapeutics is conducting preclinical research on next generation products such as combined cell-matrix products for large bone defects and maxillofacial applications or enhanced viscosupplementation for osteoarthritis. Bone Therapeutics’ cell therapy products are manufactured to the highest GMP standards and are protected by a rich Intellectual Property estate.